# Thymosin alpha-1

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Compound
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/thymosin-alpha-1-immune-modulation-and-longevity-translation.html

> Thymosin alpha-1 (thymalfasin, Zadaxin) is a 28-amino-acid thymic peptide approved in more than 35 countries for hepatitis B/C and as a cancer adjuvant, with a 2024 review covering over 11,000 subjects. The sepsis and longevity-clinic story is weaker: the largest randomized trial, TESTS (n=1,106), found no mortality benefit in sepsis, and a 2025 meta-analysis found earlier positive signals erode in high-quality trials. The live edge is oncology, where small studies position it as an immune-checkpoint-inhibitor adjunct.

## Overview

Thymosin Alpha-1 (Tα1 / thymalfasin) is a 28-amino acid thymic peptide. FDA-approved (as Zadaxin in some contexts) and approved in 35+ countries for hepatitis B/C, melanoma adjuvant. Extensively studied for immunosenescence mitigation, vaccine response enhancement in elderly, and adjunct in infections/sepsis. Off-label use in longevity clinics for immune optimization.

## Human Evidence — Approved & Large Trials (Tier 2)

  * **Approved indications** : Chronic hepatitis B/C (strong data), melanoma adjuvant, various viral/bacterial infections. Used in >35 countries.
  * **Comprehensive review (2024)** : >11,000 subjects across >30 trials; favorable safety/efficacy profile for approved uses (PMID [38308608](https://pubmed.ncbi.nlm.nih.gov/38308608/)).
  * **Aging & immunosenescence (2025 review — primary source)**: Simonova MA et al. _Aging and Thymosin Alpha-1._ Int J Mol Sci. 2025;26(23):11470. doi [10.3390/ijms262311470](https://doi.org/10.3390/ijms262311470). Preclinical + clinical data support improved vaccine response in elderly (influenza, COVID) and mitigation of immunosenescence via thymic output restoration, T-cell maturation, NK activity, Treg balance, and anti-inflammatory effects (↓ TNFα/IL-1β/IL-6, ↑ IL-10, Nrf-2 activation). Plasma Tα1 levels decline with age/inflammation.



**Mechanistic highlights (human-relevant)** : \- Enhances dendritic cell maturation, phagocytosis, HLA-DR/CD40/CD80/CD86. \- Protects thymocytes from apoptosis; promotes IL-7 expression. \- Antioxidant: neutralizes ROS, ↑ SOD, ↓ lipid peroxidation. \- CNS/CV cross-effects: hypothalamic-pituitary modulation, ACE inhibition, anti-atherosclerotic signals in models.

## Sepsis Evidence — TESTS Phase 3 (Landmark 2025)

**TESTS Trial — Wu J et al. BMJ 2025;388:e082583 (PMID[40447307](https://pubmed.ncbi.nlm.nih.gov/40447307/); DOI [10.1136/bmj-2024-082583](https://doi.org/10.1136/bmj-2024-082583)).** \- **Design** : Multicentre, double-blinded, randomised, placebo-controlled phase 3 — the largest Tα1 sepsis RCT to date. \- **Setting** : 22 centres in China; enrolment Sep 2016 → Dec 2020. \- **n** : 1,106 adults aged 18–85 with sepsis-3 diagnosis; 1:1 randomisation (Tα1 n=552 vs placebo n=554). Modified ITT analysis on 1,089 (Tα1=542, placebo=547). \- **Intervention** : Subcutaneous Tα1 1.6 mg every 12 h × 7 days (or until ICU discharge/death/withdrawal). \- **Primary endpoint** : 28-day all-cause mortality. \- **Primary result** : 23.4% (127/542) Tα1 vs 24.1% (132/547) placebo — HR 0.99, 95% CI 0.77–1.27; p=0.93 (log-rank). **No overall mortality benefit.** \- **Secondary endpoints** : No statistically significant differences (new infection, SOFA trajectory, ICU mortality, 90-day mortality, mHLA-DR recovery, Treg dynamics). \- **Safety** : No difference in adverse events. \- **Pre-specified subgroup** : Possible differential effect by age — HR 1.67 (95% CI 1.04–2.67) in <60 yr (signal toward harm) vs HR 0.81 (0.61–1.09) in ≥60 yr (numerical benefit). P-interaction = 0.04. \- **Author conclusion** : TESTS does not support routine Tα1 use in unselected adult sepsis; future trials should target elderly + chronic-disease subgroups where signals exist.

**Updated meta-analysis — Frontiers Cell Infect Microbiol Sep 2025 (PMID[40969554](https://pubmed.ncbi.nlm.nih.gov/40969554/), DOI [10.3389/fcimb.2025.1673959](https://doi.org/10.3389/fcimb.2025.1673959)):** \- Pooled 11 RCTs, n=1,927 (967 Tα1 / 960 control). \- Overall: OR 0.73 (95% CI 0.59–0.90), p=0.003 — significant 28-day mortality reduction. \- **High-quality subgroup only** : OR 0.82 (0.65–1.03), p=0.09 — _non-significant_. \- **Multicentre subgroup only** : OR 0.86 (0.68–1.08), p=0.20 — _non-significant_. \- Trial sequential analysis: required information size NOT reached → cumulative evidence at risk of false-positive; further trials needed. \- Subgroup hints (low–moderate credibility per ICEMAN): possible benefit in cancer, diabetes, coronary heart disease subgroups. \- Conclusion: signals of benefit erode as trial quality/multicentre status rises; personalised immunotherapy strategies needed.

**Interpretation** : The TESTS result effectively neutralised prior positive meta-analytic estimates. Earlier meta-analyses (Liu 2016 BMC Infect Dis, n=530) showing ~41% relative mortality reduction were underpowered and methodologically weaker. The 2025 evidence base shifts the burden of proof toward targeted-population trials; broad immunomodulation with Tα1 in undifferentiated sepsis is not supported.

**COVID-19 / other infections** : Improved T-cell recovery in lymphopenic patients; reduced mortality in severe cases in some studies; sustained IgG after vaccination in elderly.

**Evidence separation (post-TESTS):** \- Strongest: Approved antiviral/oncology uses (human RCTs). \- Moderate: Vaccine enhancement in elderly (clinical). \- Emerging: Direct longevity/immunosenescence claims (extrapolated + observational). \- **Revised** : Sepsis efficacy — broad claim downgraded; targeted subgroup signal retained but unproven.

## Preclinical / Mechanistic

  * Restores thymic function, enhances T-cell maturation and NK activity.
  * Reduces inflammatory markers; supports immune balance in aging models.
  * PANDA II trial protocol (Liu H et al., Future Cardiol 2025;21:447–454) extends Tα1 evaluation to immune modulation in acute aortic dissection surgery — a novel CV indication.



## Regulatory & Commercial Landscape

  * **FDA** : Approved for specific indications (Zadaxin); compounded versions subject to 503A/503B rules. Off-label longevity use is gray-area. | **PCAC July 23–24, 2026** : Tα1 was NOT among the seven peptides voted on for 503A inclusion (BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon, Semax). Tα1 was already reviewed at the **PCAC December 4, 2024 meeting** (alongside CJC-1295 and AOD-9604), where FDA proposed that both Tα1 (free base) and Tα1 acetate **NOT** be included on the 503A Bulks List, citing immunogenicity potential (aggregation, peptide-related impurities), absence of USP monograph, and inadequate characterization. Final rule status: as of October 2026, Tα1 remains on **FDA Category 2** (significant safety risk) — compounding pharmacies continue to source under the 503A interim policy with heightened risk. This contrasts with the July 2026 seven investigational peptides that still have an open docket. |
  * **Clinics** : Marketed by Innovative Care, Javan Anti-Aging, 360MD Austin for immune optimization.
  * **Claims audit** : Cannot claim "reverses aging" or cure disease; permitted language limited to immune support in approved contexts.
  * **Implication of TESTS** : Sepsis-related marketing claims are no longer defensible based on current highest-quality evidence.



## 2025–2026 Update: Tα1 + Immune Checkpoint Inhibitor (ICI) Synergy, Novel Chaperone Mechanism, and Active Oncology Trials

The most clinically actionable 2025–2026 signal for Tα1 is its emergence as an **ICI adjunct** — particularly in NSCLC, melanoma, and colorectal cancer — driven by two converging lines of evidence: a novel mechanistic paper (Wei/Chen/Zhang, _Cancer Research_ 2026) establishing Tα1 as a **microRNA chaperone** that licenses dendritic-cell-mediated antitumor immunity, and a comprehensive review (Frontiers in Immunology 2026) consolidating 20+ clinical datasets on Tα1+ICI combination therapy.

### Novel mechanism: Tα1 as a microRNA chaperone (Cancer Research, June 2026)

**Wei Y, Chen J, Zhang Y et al.** _Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells._ Cancer Res 2026;86(17):4238–4254. (Accepted June 10, 2026; revision April 16, 2026.)

  * **Clinical observation:** circulating Tα1 levels are **reduced** in patients after chemotherapy across multiple cancer types and in tumor-bearing mice.
  * **Mechanism (in vitro + in vivo mice):** 1\. Chemotherapy-induced tumor apoptotic bodies (ABs) carry microRNAs including **miR-146a-5p**. 2\. After DC phagocytosis of ABs, Tα1 binds and **protects miR-146a-5p from lysosomal RNase A degradation** in the endolysosomal compartment. 3\. Preserved miR-146a-5p activates **Toll-like receptor 7 (TLR7)** in DCs → DC maturation, migration to tumor-draining lymph nodes, antigen presentation, and CD8⁺ T-cell priming. 4\. Therapeutic Tα1 supplementation **synergizes with chemotherapy** to control established tumors in mice — _only_ in tumors with high miR-146a-5p expression, and **only in a TLR7-dependent manner** (knockout mice lose the effect).
  * **Significance:** Tα1 is reframed as an **endogenous miRNA chaperone** that unlocks a previously rate-limiting step in DC licensing. This explains the empirical "chemo + Tα1 works better than chemo alone" pattern in older Chinese adjuvant trials and provides a biomarker (tumor miR-146a-5p) for patient selection.
  * **Translational gap:** the synergy was demonstrated in mice; no human chemo+Tα1 RCT with the miR-146a-5p/TLR7 mechanism as the prespecified biomarker has been published. **Tier: preclinical mechanistic breakthrough; human validation pending.**



### Tα1 + ICI clinical review (Frontiers in Immunology, 2026)

**Frontiers Immunology 2026 — "Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment."** (Open-access, 2026.)

A 2026 narrative/systematic review aggregates >20 clinical datasets on Tα1 combined with PD-1/PD-L1 inhibitors (tislelizumab, nivolumab, toripalimab, pembrolizumab) across NSCLC, melanoma, colorectal cancer, and late-stage refractory solid tumors. Key findings:

Study / design | n | Indication | Regimen | Result | Safety  
---|---|---|---|---|---  
Zhang et al. (single-arm Ph2) | 20 | Locally advanced CRC | Tα1 4.8 mg 2×/wk × 11 wk + tislelizumab + neoadjuvant chemoradiation | **ORR 85% (CR 40%, PR 45%); DCR 100%** ; EFS 100% at median 10 mo | Only 1 grade 3 AE; rest grade 1–2  
Zhang & Zhou et al. (single-arm) | 9 | Stage IV melanoma, elderly, ECOG ≥2 |  | **ORR 22.2%, DCR 77.8%, mPFS 8.2 mo, mOS not reached** at 9.9 mo | All grade 1 (vitiligo, transaminitis)  
Zhang et al. (double-arm) | 48 / 101 / 47 | Locally advanced NSCLC (CCRT + nivolumab ± Tα1) | Tα1 1.6 mg qw | **PFS 14.6 vs 16.0 vs NR mo, p=0.03; OS 20.0 vs 27.6 vs NR mo, p=0.01** ; grade ≥2 pneumonitis 14.5% vs 35.4% (p=0.02) | Tα1 reduced irAE pneumonitis + lymphopenia  
Single-arm | 21 | Late-stage refractory solid tumors | Tα1 + PD-1/PD-L1 + radiotherapy + GM-CSF | ORR 23.8%, DCR 47.6% | No grade ≥3  
  
**Mechanistic rationale (per review):** Tα1 enhances immune competence while **selectively suppressing excessive activation outside the tumor microenvironment** — i.e., it shifts the immune setpoint toward tumor-specific killing while dampening ICI-induced autoimmune toxicity. The decreased pneumonitis rate (14.5% vs 35.4%) in the NSCLC CCRT-nivolumab dataset is a notable irAE-mitigation signal.

**Limitations explicitly acknowledged by the authors:** \- Predominantly single-center, small-sample trials; external validity uncertain. \- No dose-finding studies; **1.6 mg vs 4.8 mg** , **2×/wk vs 3×/wk vs daily** , treatment duration all remain unoptimized. \- High cost of Tα1 (~$150–$400 per 1.6 mg vial in the US) — no published cost-effectiveness vs irAE management costs. \- **Tier: 2 (early clinical signal; awaiting multicenter RCT).** Author conclusion: "Large-scale, multi-center clinical trials are urgently needed."

### Active 2025–2026 oncology trials (ClinicalTrials.gov)

Trial | Phase | Design | Status | Notes  
---|---|---|---|---  
**[NCT06139419](https://clinicaltrials.gov/study/NCT06139419)** (Sun Yat-sen, China) | 2 | biweekly during CCRT; Q3W during consolidation × 12 mo) | Active, not recruiting; **completed Aug 30, 2026** | n=114. Primary: completion rate of IO consolidation. 2-yr OS, 1-yr PFS, ≥grade 2 pneumonia  
**[NCT06607926](https://clinicaltrials.gov/study/NCT06607926)** | 2/3 (Ph2 portion) |  | Recruiting | Multi-center RCT; primary pathologic response rate  
**[NCT06178146](https://clinicaltrials.gov/study/NCT06178146)** (Jun Wang, China) | 4 (post-marketing) | Tα1 1.6 mg for **ICI-induced irAEs** vs conventional immunosuppression | Completed April 2025; status "Unknown" (awaiting publication) | n=40. Tests Tα1 as irAE rescue therapy  
  
### Implications for evidence tier

The 2025–2026 Tα1 evidence base has **expanded upward** in oncology (from "approved antiviral/oncology adjuvant" to "rational ICI combination partner with mechanistic biomarker") while remaining **stable-to-downgraded** in non-oncology indications: \- **Upgraded:** Tα1 + ICI in geriatric oncology (well-defined biological rationale, multiple Phase 2 signals, plausible biomarker miR-146a-5p). \- **Stable:** approved antiviral/melanoma adjuvant uses; vaccine enhancement in elderly. \- **Downgraded (post-TESTS):** undifferentiated sepsis; broad "immune booster" longevity claims. \- **New investigational:** irAE management ([NCT06178146](https://clinicaltrials.gov/study/NCT06178146)).

### Open questions

  * Does the miR-146a-5p/TLR7 chaperone mechanism explain the better performance in elderly patients (TESTS subgroup signal) or in NSCLC CCRT-pneumonitis datasets?
  * Will the Sun Yat-sen [NCT06139419](https://clinicaltrials.gov/study/NCT06139419) (results expected late 2026 / early 2027) confirm the NSCLC CCRT-IO consolidation signal?
  * Will [NCT06178146](https://clinicaltrials.gov/study/NCT06178146) (irAE management) publish in 2026, validating Tα1 as an irAE rescue rather than a primary oncology agent?



### Key 2025–2026 sources added

  * **Wei Y et al._Cancer Res_ 2026;86(17):4238–4254** — Tα1 as miR-146a-5p chaperone → TLR7 licensing in DCs
  * **Frontiers Immunology 2026** — Tα1 + ICI synergy review (open-access)
  * **ClinicalTrials.gov[NCT06139419](https://clinicaltrials.gov/study/NCT06139419)** — Sun Yat-sen NSCLC, Tα1 4.8 mg + tislelizumab consolidation, completed Aug 2026
  * **ClinicalTrials.gov[NCT06607926](https://clinicaltrials.gov/study/NCT06607926)** — neoadjuvant NSCLC, Tα1 4.8 mg 2×/wk × 12 wk
  * **ClinicalTrials.gov[NCT06178146](https://clinicaltrials.gov/study/NCT06178146)** — Tα1 for ICI-induced irAEs, completed Apr 2025
  * **ClinicalTrials.gov[NCT06821100](https://clinicaltrials.gov/study/NCT06821100)** — Methodist Hospital, Tα1 + COVID-19 vaccine booster in adults 65–100, recruiting through Dec 2026
  * **FDA PCAC Dec 4, 2024 briefing (FDA-2024-N-3534-0470)** — Tα1 evaluation; FDA proposed NOT to include on 503A Bulks List (immunogenicity + characterization concerns)
  * **FDA Category 2 list** — Tα1 remains on Category 2 for compounded injectable use (potential immunogenicity, peptide-related impurities)



_Updated 2026-10-04. No therapeutic advice. Verify all clinical-trial status on ClinicalTrials.gov before citing._

## Sources

1. PMID 38308608 (2024) — Comprehensive safety/efficacy review (>11k subjects) (PubMed 38308608)
2. DOI 10.3390/ijms262311470 (DOI 10.3390/ijms262311470)
3. Wu J et al. (2025) BMJ 388:e082583 — TESTS Phase 3 RCT (n=1,106) — PMID 40447307 — landmark negative trial, now anchors sepsis evidence (PubMed 40447307)
4. DOI 10.1136/bmj-2024-082583 (DOI 10.1136/bmj-2024-082583)
5. Frontiers Cell Infect Microbiol (Sep 2025) — PMID 40969554 — updated 11-RCT meta-analysis with TSA; signals weaker in high-quality trials (PubMed 40969554)
6. DOI 10.3389/fcimb.2025.1673959 (DOI 10.3389/fcimb.2025.1673959)
7. ClinicalTrials.gov (sepsis NCT02867267 , hepatitis, COVID trials; ongoing NCT06821100 for vaccine enhancement) (NCT02867267, NCT06821100)
8. NCT06139419 (NCT06139419)
9. NCT06607926 (NCT06607926)
10. NCT06178146 (NCT06178146)